Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify the source of chronic low back pain, announced the appointment of Daniel Keefe as Commercial Director, Western U.S. The move comes as the company reports triple-digit growth in utilization of its Nociscan platform, signaling increasing demand for objective, noninvasive diagnostic tools in spine care.
Keefe brings more than 20 years of experience in medical device and healthcare technology sales, with leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, as Regional Sales Manager at Centinel Spine, he consistently exceeded performance targets and delivered significant year-over-year growth across Northern California. His appointment reflects Aclarion's strategy to deepen its presence in a key region where the company has already established a footprint with academic institutions and high-volume private practice spine centers.
“Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies,” said Brent Ness, Chief Executive Officer of Aclarion. “His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan.”
Chronic low back pain affects an estimated 266 million people worldwide, making it one of the most pervasive health challenges. Aclarion's Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The platform uses magnetic resonance spectroscopy data from an MRI machine to quantify chemical biomarkers associated with disc pain, then applies proprietary algorithms to indicate whether a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
The appointment of Keefe is part of a broader expansion of Aclarion's commercial team, supported by strong volume growth and increasing demand for the technology. Keefe will lead efforts across the Western region, building on Aclarion's existing engagement with spine centers and aiming to deepen adoption. “I’m excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community,” said Keefe. “The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice.”
The implications of this appointment are significant for the spine care industry. As healthcare moves toward value-based care and precision medicine, tools like Nociscan that provide objective data to guide treatment decisions can reduce unnecessary surgeries and improve outcomes. The triple-digit growth in Nociscan utilization suggests that physicians are recognizing the value of biomarker-based diagnostics. Aclarion's focus on the Western U.S., a region with a large population and numerous leading spine centers, positions the company to capture a substantial share of the chronic low back pain diagnostic market. For patients, broader access to Nociscan could mean more accurate diagnoses and tailored treatment plans, potentially reducing the burden of chronic pain. For more information on Nociscan, view the site map here. For more about Aclarion, visit www.aclarion.com.
